General MedicationsINTRAVENOUSStandard
ONPATTRO
PATISIRAN SODIUM
Standard Dose
EQ 10MG BASE/5ML (EQ 2MG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ONPATTRO is listed in Drugs@FDA under application 210922 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient PATISIRAN SODIUM Form and strength SOLUTION;INTRAVENOUS - EQ 10MG BASE/5ML (EQ 2MG BASE/ML) Sponsor ALNYLAM PHARMS INC Submission history Latest submission status date: 2023-01-13 00:00:00.
Structured Monograph
Clinical summary
Approval overview ONPATTRO is listed in Drugs@FDA under application 210922 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PATISIRAN SODIUM Form and strength SOLUTION;INTRAVENOUS - EQ 10MG BASE/5ML (EQ 2MG BASE/ML) Sponsor ALNYLAM PHARMS INC Submission history Latest submission status date: 2023-01-13 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.